10th MASH Drug Development Summit 2026
Ev sahibi Hanson Wade
- 15 – 17 September 2026
- The Colonnade Boston, Boston, United States of America
- Health SciencesEczacılık ve Farmasötik Bilimler
Orada olacağınızı başkalarına bildirin. Bu işlem sizi etkinliğe kaydetmez.
Kayıt
Etkinlik sona erdiKayıt organizatör tarafından yapılıyor
Ücretler bu sayfada listelenmiştir
Kayıt bilgilerini görTemel bilgiler
10th MASH Drug Development Summit 2026, Hanson Wade tarafından 15 – 17 Eylül 2026 tarihlerinde The Colonnade Boston, Boston, Amerika Birleşik Devletleri konumunda düzenlenen bir zirve etkinliğidir.
- Tarihler:
- 15 – 17 Eylül 2026
- Biçim:
- Yüz yüze
- Mekân:
- The Colonnade Boston, Boston, Amerika Birleşik Devletleri
- Konular:
- Pharmacy & Pharmaceutical Sciences
- Organizatör:
- Hanson Wade
- Resmi web sitesi:
- mashdrugdevelopmentsummit.com
The 10th MASH Drug Development Summit is the premier industry forum dedicated exclusively to advancing MASH therapeutics from discovery through clinical development. Organised by Hanson Wade, the event takes place from September 15–17, 2026, at The Colonnade in Boston, MA. Bringing together senior leaders across discovery, translational science, clinical development, biomarkers, and regulatory strategy, the summit uniquely combines a focus on human-relevant preclinical models, non-invasive biomarkers, AI-enabled pathology, and advanced combination strategies to tackle the evolving post-approval landscape of metabolic dysfunction-associated steatohepatitis.
Konferans teması
Programdan öne çıkanlar
Programın tamamını görDavetli konuşmacı
Programı görDavetli konuşmacı
Scientific Director & Associate Research Fellow, Pfizer
Targeting Thyroid Hormone Receptor-Β Pathways To Reduce Liver Fibrosis, Improve Metabolic Function & Enable Durable Clinical Benefit In MashDavetli konuşmacı
Senior Director, Metabolic Diseases, Insitro
Integrating AI/Ml With Disease Biology To Identify Differentiated Novel Mash TargetsDavetli konuşmacı
CEO & Founder, Viscient Biosciences
Developing MASH Therapeutics Utilizing Complex 3D Human In Vitro, In Vivo & Ex Vivo Models to Validate MASH Therapeutic Efficacy Across SystemsDavetli konuşmacı
Vice President, Discovery Biology, Sepia Therapeutics
Exploring Epigenetic Editing Approaches to Target Fibrotic Drivers, Enable Precision Modulation & Expand Next-Generation MASH Therapeutic StrategiesDavetli konuşmacı
Chief Executive Officer, Cirius Therapeutics
Tailoring Combination Strategies to Address Disease Heterogeneity & Improve Therapeutic OutcomesDavetli konuşmacı
Founder, Director & Senior Scientific & Medical Advisor, Madrigal Pharmaceuticals
Adapting Mash Development Strategies Within An Evolving Treatment Landscape To Define Clinical Value, Enable Differentiation & Establish Future Standards Of Carekongre.net'te 2 konferansDavetli konuşmacı
Medical Director, Global Clinical Development, Late Stage Cardiovascular, Renal & Metabolism, AstraZeneca
Advancing Genetically Validated Targets & Combination Development Strategies to Improve Therapeutic Precision, Enable Differentiation & Support Long-Term Success in MASHDavetli konuşmacı
Vice President, Head of Clinical Development, Rivus Pharmaceuticals
Leveraging an Energy Expenditure Mechanism to Drive Liver-Targeted Reductions in Fat and Inflammation, the Primary Drivers of MASHDavetli konuşmacı
Associate Director, Clinical Research, Akero Therapeutics
Demonstrating Fibrosis Regression Through Non-Invasive Assessments in the Ph2b SYMMETRY Trial of Efruxifermin: Advancing Development in Compensated Cirrhosis Due to MASHDavetli konuşmacı
Associate Professor of Medicine & Director, Liver Fibrosis Research, Beth Israel Deaconess Medical Center
Targeting Cirrhosis & Fibrotic Complications To Improve Translational Relevance, Enable Late-Stage Intervention & Expand Therapeutic Impact In MashDavetli konuşmacı
Director, Translational Science, Metabolism Corcept Therapeutics, Corcept Therapeutics
Identifying High-Risk Patient Populations Through Clinical & Biomarker Insights to Enable Earlier Intervention & Improve Long-Term Outcomes in MASHDavetli konuşmacı
Faculty, Harvard Medical School and Mass General Brigham
Neuro-Immuno-Metabolic Regulation of MASH ProgressionDavetli konuşmacı
Chief Scientific Officer, Vertero Therapeutics
Targeting Bile Salt Hydrolase with the Oral Small Molecule VT-6382 as a Novel and Differentiated Approach to Treating MASH and Liver Fibrosis
Konuşmacılar
22 konuşmacının tümünü görSelma BoulenouarDavetli konuşmacı
Harvard Medical School and Mass General Brigham
Neuro-Immuno-Metabolic Regulation of MASH Progression
Organizatör ve iletişim
İletişim
- Etkinlik sekreteryası:
- Anna Westgate-Maher
- E-posta:
- [email protected]
Reklam
İlgili etkinlikler
- 11th Microbiome Movement USA SummitBoston, Amerika Birleşik Devletleri9–11 Nov 2026
- 9th RNA-Targeted Drug Discovery & Development SummitBoston, Amerika Birleşik Devletleri10–12 Nov 2026
- Protein Design & Engineering Summit 2026Boston, Amerika Birleşik Devletleri10–12 Nov 2026
- Biomarker Operations & Biospecimen Management SummitBoston, Amerika Birleşik Devletleri16–17 Nov 2026
- U.S Biotech Day 2026Philadelphia, Amerika Birleşik Devletleri16–17 Nov 2026
- 2nd Model-Informed Drug Development SummitBoston, Amerika Birleşik Devletleri17–19 Nov 2026